{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:44:56Z","timestamp":1794296696701,"version":"4.9.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eururo.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:45:58Z","timestamp":1747669558000},"page":"129-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"88","author":[{"given":"Elio","family":"Mazzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Cannoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon L.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.05.006_b0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.05.006_b0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.05.006_b0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2021.07.027","article-title":"Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups","volume":"81","author":"Mazzone","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2025.05.006_b0030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.05.006_b0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijrobp.2017.06.2448","article-title":"Prostate-specific membrane antigen positron emission tomography\u2013computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning","volume":"99","author":"Gupta","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.006_b0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2025.05.006_b0075","first-page":"10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.eururo.2025.05.006_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0095","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.05.006_b0105","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2025.05.006_b0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.121.262412","article-title":"A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients","volume":"63","author":"Abghari-Gerst","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.006_b0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bco2.151","article-title":"Cribriform pattern disease over-represented in pelvic lymph node metastases identified on 68GA PSMA-PET\/CT","volume":"3","author":"Bolton","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2025.05.006_b0125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","article-title":"68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy","volume":"46","author":"Ceci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/diagnostics12020349","article-title":"Identification of the optimal cut-off value of PSA for assessing severity of disease in [68Ga]Ga-PSMA-11 PET\/CT study in prostate cancer patients after radical prostatectomy","volume":"12","author":"Cegla","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.eururo.2025.05.006_b0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2967\/jnumed.120.261886","article-title":"Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET\/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study)","volume":"63","author":"Cerci","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/diagnostics12010195","article-title":"Evaluation of predictors of biochemical recurrence in prostate cancer patients, as detected by 68Ga-PSMA PET\/CT","volume":"12","author":"Christensen","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.eururo.2025.05.006_b0150","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1111\/ajco.13595","article-title":"68Ga-prostate-specific membrane antigen (PSMA) PET\/CT as a clinical decision-making tool in biochemically recurrent prostate cancer","volume":"18","author":"Davies","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2025.05.006_b0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euros.2022.05.011","article-title":"Defining prostatic vascular pedicle recurrence and the anatomy of local recurrence of prostate cancer on prostate-specific membrane antigen positron emission tomography\/computed tomography","volume":"41","author":"Dundee","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.05.006_b0165","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2967\/jnumed.116.184457","article-title":"Detection efficacy of hybrid 68Ga-PSMA ligand PET\/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria","volume":"58","author":"Einspieler","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0170","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2967\/jnumed.118.220103","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0175","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12094-020-02427-2","article-title":"Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET\/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series","volume":"23","author":"Francolini","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0185","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-023-06483-y","article-title":"Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET\/MRI and [68Ga]Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial","volume":"51","author":"Ghezzo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0190","first-page":"77","article-title":"A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy \u2013 the PROPER 1 trial","volume":"36","author":"Gunnlaugsson","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0195","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/pros.23347","article-title":"68Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment","volume":"77","author":"Habl","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.05.006_b0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/diagnostics12092212","article-title":"PSA-stratified performance of [18F]DCFPyL PET\/CT in biochemically recurrent prostate cancer patients under androgen deprivation therapy","volume":"12","author":"Harsini","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.eururo.2025.05.006_b0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/HP.0000000000001253","article-title":"Diagnostic performance of 68Ga-PSMA-11 positron-emission-tomography\/computed-tomography in a large cohort of patients with biochemical recurrence of prostate carcinoma","volume":"119","author":"Hoffmann","year":"2020","journal-title":"Health Phys"},{"key":"10.1016\/j.eururo.2025.05.006_b0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/cancers14061479","article-title":"Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET\/CT in restaging of prostate cancer patients with PSA relapse","volume":"14","author":"Hoffmann","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.05.006_b0215","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1007\/s00330-023-10442-4","article-title":"Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET\/MRI","volume":"34","author":"Jannusch","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.05.006_b0220","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1007\/s00259-021-05354-8","article-title":"Patterns of disease detection using [18F]DCFPyL PET\/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial","volume":"48","author":"Koschel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0225","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/jcm10173883","article-title":"Pattern of prostate cancer recurrence assessed by 68Ga-PSMA-11 PET\/CT in men treated with primary local therapy","volume":"10","author":"Lawal","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0230","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ijrobp.2019.11.001","article-title":"A prospective study of 18F-DCFPyL PSMA PET\/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy","volume":"106","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.05.006_b0235","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JU.0000000000001064","article-title":"Prostate specific antigen and prostate specific antigen doubling time predict findings on 18F-DCFPyL positron emission tomography\/computerized tomography in patients with biochemically recurrent prostate cancer","volume":"204","author":"Markowski","year":"2020","journal-title":"J Urol"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2025.05.006_b0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.13616","article-title":"The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","volume":"118","author":"Meredith","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.006_b0245","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3390\/curroncol28050282","article-title":"18F-DCFPyL (PSMA) PET in the management of men with biochemical failure after primary therapy: initial clinical experience of an academic cancer center","volume":"28","author":"Metser","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0250","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00259-020-04718-w","article-title":"Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET\/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy","volume":"47","author":"Miksch","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109556","article-title":"PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications","volume":"136","author":"Morawitz","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2025.05.006_b0260","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/wjnm.WJNM_47_18","article-title":"Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography\/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients","volume":"18","author":"Natarajan","year":"2019","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0265","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","article-title":"A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT","volume":"44","author":"Pernthaler","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0270","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12149-018-1275-7","article-title":"Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET\/CT and PET\/MR scans in recurrent prostate cancer patients","volume":"32","author":"Ringheim","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0275","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A prospective study on 18F-DCFPYL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective evaluation of PSMA-targeted 18F-DCFPyL PET\/CT in men with biochemical failure after radical prostatectomy for prostate cancer","volume":"61","author":"Rowe","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0285","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","article-title":"Biphasic 68Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma","volume":"43","author":"Sahlmann","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0290","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2967\/jnumed.118.220855","article-title":"Impact of 68Ga-PSMA PET\/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-0983-4","article-title":"Outcome after PSMA PET\/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy","volume":"13","author":"Schmidt-Hegemann","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.05.006_b0300","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT\u2013based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"68Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","author":"Sterzing","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0310","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1007\/s00259-023-06355-5","article-title":"Total-body [68Ga]Ga-PSMA-11 PET\/CT improves detection rate compared with conventional [68Ga]Ga-PSMA-11 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0315","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1007\/s00259-024-06674-1","article-title":"The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET\/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET\/CT for early recurrent prostate cancer patients with PSA <0.2 ng\/ml after radical prostatectomy","volume":"51","author":"Wang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.05.006_b0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.semnuclmed.2024.05.004","article-title":"Long axial field-of-view (LAFOV) PET\/CT in prostate cancer","volume":"55","author":"Sachpekidis","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2025.05.006_b0325","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1007\/s00259-021-05461-6","article-title":"Long axial field of view PET scanners: a road map to implementation and new possibilities","volume":"48","author":"Slart","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:30:54Z","timestamp":1762288254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0302283825002854"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.006","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}